These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 36356965)
1. Effects of rifampicin, Zhang L; Meng X; Dong P; Qi T; Liu L; Wang B Int J STD AIDS; 2023 Jan; 34(1):37-47. PubMed ID: 36356965 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy. Lee KY; Lin SW; Sun HY; Kuo CH; Tsai MS; Wu BR; Tang SY; Liu WC; Chang SY; Hung CC PLoS One; 2014; 9(2):e88497. PubMed ID: 24551111 [TBL] [Abstract][Full Text] [Related]
3. CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure. Mukonzo JK; Nanzigu S; Waako P; Ogwal-Okeng J; Gustafson LL; Aklillu E Pharmacogenomics; 2014 Aug; 15(11):1423-35. PubMed ID: 25303294 [TBL] [Abstract][Full Text] [Related]
4. The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients. Bienvenu E; Swart M; Dandara C; Ashton M Antiviral Res; 2014 Feb; 102():44-53. PubMed ID: 24316028 [TBL] [Abstract][Full Text] [Related]
5. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. Manosuthi W; Sukasem C; Lueangniyomkul A; Mankatitham W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S Antimicrob Agents Chemother; 2013 Feb; 57(2):1019-24. PubMed ID: 23254426 [TBL] [Abstract][Full Text] [Related]
6. Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial. Gallien S; Journot V; Loriot MA; Sauvageon H; Morlat P; Reynes J; Reliquet V; Chêne G; Molina JM; HIV Med; 2017 Sep; 18(8):537-545. PubMed ID: 28145050 [TBL] [Abstract][Full Text] [Related]
7. Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. Mukonzo JK; Okwera A; Nakasujja N; Luzze H; Sebuwufu D; Ogwal-Okeng J; Waako P; Gustafsson LL; Aklillu E BMC Infect Dis; 2013 Jun; 13():261. PubMed ID: 23734829 [TBL] [Abstract][Full Text] [Related]
8. High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment. von Braun A; Castelnuovo B; Ledergerber B; Cusato J; Buzibye A; Kambugu A; Fehr J; Calcagno A; Lamorde M; Sekaggya-Wiltshire C J Antimicrob Chemother; 2019 Jan; 74(1):135-138. PubMed ID: 30239753 [TBL] [Abstract][Full Text] [Related]
9. Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. Uttayamakul S; Likanonsakul S; Manosuthi W; Wichukchinda N; Kalambaheti T; Nakayama EE; Shioda T; Khusmith S AIDS Res Ther; 2010 Mar; 7():8. PubMed ID: 20338069 [TBL] [Abstract][Full Text] [Related]
10. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Cohen K; Grant A; Dandara C; McIlleron H; Pemba L; Fielding K; Charalombous S; Churchyard G; Smith P; Maartens G Antivir Ther; 2009; 14(5):687-95. PubMed ID: 19704172 [TBL] [Abstract][Full Text] [Related]
11. CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe. Dhoro M; Zvada S; Ngara B; Nhachi C; Kadzirange G; Chonzi P; Masimirembwa C BMC Pharmacol Toxicol; 2015 Mar; 16():4. PubMed ID: 25889207 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. Kwara A; Lartey M; Sagoe KW; Xexemeku F; Kenu E; Oliver-Commey J; Boima V; Sagoe A; Boamah I; Greenblatt DJ; Court MH J Clin Pharmacol; 2008 Sep; 48(9):1032-40. PubMed ID: 18728241 [TBL] [Abstract][Full Text] [Related]
13. Plasma levels of efavirenz and frequency of the CYP2B6 516G>T polymorphism in people living with HIV-1 in Mexico. Ortíz-Rodríguez MA; Oaxaca-Navarro J; Patiño-Camacho SI; García-Jiménez S; Déciga-Campos M; Martínez-Salazar MF Pharmazie; 2022 Jun; 77(6):191-195. PubMed ID: 35751161 [TBL] [Abstract][Full Text] [Related]
14. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations. Ngaimisi E; Habtewold A; Minzi O; Makonnen E; Mugusi S; Amogne W; Yimer G; Riedel KD; Janabi M; Aderaye G; Mugusi F; Bertilsson L; Aklillu E; Burhenne J PLoS One; 2013; 8(7):e67946. PubMed ID: 23861838 [TBL] [Abstract][Full Text] [Related]
15. Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype. Kitabi EN; Minzi OMS; Mugusi S; Sasi P; Janabi M; Mugusi F; Bertilsson L; Burhenne J; Aklillu E Sci Rep; 2018 Nov; 8(1):16316. PubMed ID: 30397233 [TBL] [Abstract][Full Text] [Related]
17. Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand. Chaivichacharn P; Avihingsanon A; Manosuthi W; Ubolyam S; Tongkobpetch S; Shotelersuk V; Punyawudho B Clin Ther; 2020 Jul; 42(7):1234-1245. PubMed ID: 32451120 [TBL] [Abstract][Full Text] [Related]
18. Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study. Habtewold A; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Burhenne J; Aklillu E Pharmacogenomics; 2015; 16(10):1047-64. PubMed ID: 25831219 [TBL] [Abstract][Full Text] [Related]
19. CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Kwara A; Lartey M; Sagoe KW; Rzek NL; Court MH Br J Clin Pharmacol; 2009 Apr; 67(4):427-36. PubMed ID: 19371316 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. Ngaimisi E; Minzi O; Mugusi S; Sasi P; Riedel KD; Suda A; Ueda N; Bakari M; Janabi M; Mugusi F; Bertilsson L; Burhenne J; Aklillu E; Diczfalusy U J Antimicrob Chemother; 2014 Dec; 69(12):3311-9. PubMed ID: 25096076 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]